Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Tivity Health's (TVTY) Shares Fall Despite Q3 Earnings Beat
by Zacks Equity Research
Tivity Health (TVTY) reports solid revenue growth in its Nutrition arm in the third quarter due to strength in Nutrisystem brand DTC.
HMS Holdings (HMSY) Climbs 7.4% Post In-Line Q3 Earnings
by Zacks Equity Research
HMS Holdings (HMSY) witnessed revenue growth in COB and PI segments in the third quarter.
Owens & Minor's (OMI) Shares Fall Despite Q3 Earnings Beat
by Zacks Equity Research
Owens & Minor (OMI) reports solid revenue growth in its Global Products arm in the third quarter due to strength in PPE sales.
AMN Healthcare (AMN) Loses 9.4% Despite Q3 Earnings Beat
by Zacks Equity Research
AMN Healthcare (AMN) gained from Technology and Workforce Solutions segment in the third quarter.
Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)
by Zacks Equity Research
Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.
Hill-Rom (HRC) Q4 Earnings, Revenues Top Estimates, Fall Y/Y
by Zacks Equity Research
In Q3, Hill-Rom's (HRC) bed orders and backlog in the United States accelerates with sequential recovery in Patient Support Systems arm.
Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3
by Zacks Equity Research
Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.
Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.
Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates
by Zacks Equity Research
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.
Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.
Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
CVS Health (CVS) Q3 Earnings Top Estimates, 2020 View Up
by Zacks Equity Research
CVS Health's (CVS) Q3 pharmacy claims processed rise attributable to strong net new business, partially offset by reduced new therapy prescriptions.
Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.
Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.
LHC Group (LHCG) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LHC Group's (LHCG) third-quarter results benefit from organic growth in home health as well hospice admissions.
Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.
Inogen (INGN) Stock Loses 9.2% After Delivering Loss in Q3
by Zacks Equity Research
Inogen (INGN) saw revenue decline within its Sales segment in Q3
PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat
by Zacks Equity Research
PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.
Becton Dickinson (BDX) Earnings Surpass Estimates in Q4
by Zacks Equity Research
Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in the fiscal fourth quarter.
DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) rides high on the launch of the Axeos imaging system in the third quarter.
Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.
Insulet (PODD) Q3 Earnings & Revenues Top Estimates, View Up
by Zacks Equity Research
Insulet's (PODD) Q3 gross margin improvement can be primarily attributed to performance of the company's U.S. manufacturing and favorable revenue mix from the shift to higher volume